Humana (NYSE:HUM) Stock Price Down 1.1% Following Analyst Downgrade

Humana Inc. (NYSE:HUM) traded down 1.1% during mid-day trading on Friday after Royal Bank of Canada lowered their price target on the stock from $415.00 to $353.00. Royal Bank of Canada currently has an outperform rating on the stock. Humana traded as low as $307.00 and last traded at $308.01. 304,738 shares traded hands during trading, a decline of 85% from the average session volume of 1,983,508 shares. The stock had previously closed at $311.41.

Several other equities research analysts have also issued reports on HUM. Deutsche Bank Aktiengesellschaft lowered shares of Humana from a “buy” rating to a “hold” rating and decreased their price target for the stock from $595.00 to $360.00 in a research note on Thursday, January 25th. UBS Group dropped their price target on Humana from $334.00 to $326.00 and set a “neutral” rating on the stock in a research report on Thursday. TD Cowen cut their price target on Humana from $427.00 to $396.00 and set a “buy” rating for the company in a research note on Tuesday, April 2nd. Truist Financial restated a “hold” rating and issued a $550.00 price objective on shares of Humana in a research note on Friday, January 19th. Finally, The Goldman Sachs Group cut their target price on shares of Humana from $450.00 to $385.00 and set a “buy” rating for the company in a research report on Wednesday, April 3rd. Eleven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $433.74.

Insider Buying and Selling

In related news, Director Jorge S. Mesquita acquired 545 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were bought at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the transaction, the director now owns 2,578 shares in the company, valued at $946,358.02. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.32% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Morgan Stanley boosted its holdings in shares of Humana by 6.2% in the 3rd quarter. Morgan Stanley now owns 2,040,896 shares of the insurance provider’s stock worth $992,938,000 after purchasing an additional 119,760 shares in the last quarter. Ameriprise Financial Inc. lifted its position in Humana by 35.9% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,523,835 shares of the insurance provider’s stock worth $741,409,000 after buying an additional 402,559 shares during the last quarter. Norges Bank purchased a new stake in Humana in the fourth quarter worth approximately $676,800,000. Northern Trust Corp grew its position in Humana by 5.1% during the third quarter. Northern Trust Corp now owns 1,327,489 shares of the insurance provider’s stock valued at $645,850,000 after acquiring an additional 64,245 shares during the last quarter. Finally, Sanders Capital LLC purchased a new position in shares of Humana during the fourth quarter worth approximately $489,300,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Trading Down 1.1 %

The stock has a market capitalization of $37.17 billion, a P/E ratio of 19.18, a price-to-earnings-growth ratio of 1.85 and a beta of 0.45. The stock’s fifty day moving average price is $328.56 and its two-hundred day moving average price is $395.71. The company has a current ratio of 1.67, a quick ratio of 1.59 and a debt-to-equity ratio of 0.77.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, topping the consensus estimate of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The business had revenue of $29.61 billion during the quarter, compared to the consensus estimate of $28.52 billion. During the same period in the previous year, the firm posted $9.38 earnings per share. The firm’s revenue for the quarter was up 10.7% on a year-over-year basis. Equities research analysts forecast that Humana Inc. will post 16.06 EPS for the current year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.54 annualized dividend and a yield of 1.15%. Humana’s payout ratio is 22.04%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.